lutetium-lu-177-dotatate and Pancreatitis

lutetium-lu-177-dotatate has been researched along with Pancreatitis* in 1 studies

Other Studies

1 other study(ies) available for lutetium-lu-177-dotatate and Pancreatitis

Article	Year
Acute Pancreatitis Following Peptide Receptor Radionuclide Therapy: An Unusual Adverse Event. Clinical nuclear medicine, 2018, Volume: 43, Issue:7 A 54-year-old man with grade 2 rectal neuroendocrine tumor and hepatic, pancreatic, and bone metastases was treated with Lu-DOTATATE as second-line therapy, after failure of somatostatin analogues. Two weeks after the first injection, he presented at the emergency department with acute pancreatitis. We hypothesized that this unusual adverse event, never been reported so far, was the result of acute tumor irradiation after PRRT, leading to peritumoral inflammation and edema with obstruction of an accessory pancreatic duct. Topics: Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatitis; Radiopharmaceuticals; Rectal Neoplasms	2018

Article

Year

Acute Pancreatitis Following Peptide Receptor Radionuclide Therapy: An Unusual Adverse Event.

Clinical nuclear medicine, 2018, Volume: 43, Issue:7

A 54-year-old man with grade 2 rectal neuroendocrine tumor and hepatic, pancreatic, and bone metastases was treated with Lu-DOTATATE as second-line therapy, after failure of somatostatin analogues. Two weeks after the first injection, he presented at the emergency department with acute pancreatitis. We hypothesized that this unusual adverse event, never been reported so far, was the result of acute tumor irradiation after PRRT, leading to peritumoral inflammation and edema with obstruction of an accessory pancreatic duct.

Topics: Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatitis; Radiopharmaceuticals; Rectal Neoplasms

2018